KR102504849B1 - 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 - Google Patents

치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 Download PDF

Info

Publication number
KR102504849B1
KR102504849B1 KR1020177010551A KR20177010551A KR102504849B1 KR 102504849 B1 KR102504849 B1 KR 102504849B1 KR 1020177010551 A KR1020177010551 A KR 1020177010551A KR 20177010551 A KR20177010551 A KR 20177010551A KR 102504849 B1 KR102504849 B1 KR 102504849B1
Authority
KR
South Korea
Prior art keywords
amino
substituted
compound
pyran
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010551A
Other languages
English (en)
Korean (ko)
Other versions
KR20170063740A (ko
Inventor
매튜 알렉산더
소고르 바만야
존 프레드레릭 보이랜
조슈아 한센
더화 황
로버트 허바드
브랜돈 제피
짐 레이스텐
메흐란 모가담
라즈 케이. 라헤자
헤더 레이몬
킴버리 슈바르츠
마리안느 슬로스
에두아르도 토레스
탐 민 트란
슈이찬 슈
징징 자오
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Priority to KR1020237006598A priority Critical patent/KR20230035424A/ko
Publication of KR20170063740A publication Critical patent/KR20170063740A/ko
Application granted granted Critical
Publication of KR102504849B1 publication Critical patent/KR102504849B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177010551A 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 Active KR102504849B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237006598A KR20230035424A (ko) 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237006598A Division KR20230035424A (ko) 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법

Publications (2)

Publication Number Publication Date
KR20170063740A KR20170063740A (ko) 2017-06-08
KR102504849B1 true KR102504849B1 (ko) 2023-03-02

Family

ID=55632334

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177010551A Active KR102504849B1 (ko) 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
KR1020237006598A Withdrawn KR20230035424A (ko) 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237006598A Withdrawn KR20230035424A (ko) 2014-10-06 2015-10-05 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법

Country Status (28)

Country Link
US (8) US9512124B2 (https=)
EP (2) EP3822274B1 (https=)
JP (4) JP6884701B2 (https=)
KR (2) KR102504849B1 (https=)
CN (2) CN107001372B (https=)
AR (2) AR102171A1 (https=)
AU (2) AU2015328414B2 (https=)
CA (1) CA2963639C (https=)
CL (1) CL2017000820A1 (https=)
CO (1) CO2017003838A2 (https=)
CY (1) CY1124173T1 (https=)
DK (1) DK3204386T3 (https=)
EA (1) EA201790779A1 (https=)
EC (1) ECSP17026210A (https=)
ES (2) ES2980464T3 (https=)
HR (1) HRP20210656T1 (https=)
HU (1) HUE054694T2 (https=)
IL (2) IL251566B (https=)
LT (1) LT3204386T (https=)
MX (2) MX388321B (https=)
PL (1) PL3204386T3 (https=)
PT (1) PT3204386T (https=)
RS (1) RS61884B1 (https=)
SG (2) SG11201702759XA (https=)
SI (1) SI3204386T1 (https=)
SM (1) SMT202100302T1 (https=)
TW (1) TW201629063A (https=)
WO (1) WO2016057370A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
WO2016149439A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of tnf
CA3208587A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
RS62496B1 (sr) * 2016-04-01 2021-11-30 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu
AU2017241837B2 (en) * 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN109563095B (zh) * 2016-06-02 2021-10-29 细胞基因公司 动物和人抗疟剂
EP3464312A4 (en) * 2016-06-02 2019-11-27 Celgene Corporation ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS
MX2020003620A (es) * 2017-10-04 2020-10-28 Celgene Corp Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida.
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法
CN117964497B (zh) * 2024-01-26 2026-03-31 江西凯信生物医药有限公司 一种3,3-二氟环戊胺盐酸盐的合成方法
CN121758295A (zh) * 2024-09-30 2026-03-31 青岛清原化合物有限公司 一种亚氨基芳基类化合物及中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191086A1 (en) 1999-01-26 2003-10-09 Ustav Experimentalni Botaniky Av Cr Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
US20080021048A1 (en) 2005-01-13 2008-01-24 Bennett Brydon L Methods of treatment and prevention using haloaryl substituted aminopurines
US20120129807A1 (en) 2010-10-25 2012-05-24 Bennett Brydon L Methods of treatment, improvement and prevention using haloaryl substituted aminopurines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) * 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
NZ598071A (en) 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
WO2009130342A1 (es) 2008-04-23 2009-10-29 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
RS62496B1 (sr) 2016-04-01 2021-11-30 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trihlorofenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamid i postupci za njegovu upotrebu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191086A1 (en) 1999-01-26 2003-10-09 Ustav Experimentalni Botaniky Av Cr Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
US20080021048A1 (en) 2005-01-13 2008-01-24 Bennett Brydon L Methods of treatment and prevention using haloaryl substituted aminopurines
US20120129807A1 (en) 2010-10-25 2012-05-24 Bennett Brydon L Methods of treatment, improvement and prevention using haloaryl substituted aminopurines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chen, X. et al., Neoplasma, 2014, 61, 514-522

Also Published As

Publication number Publication date
AR102171A1 (es) 2017-02-08
PT3204386T (pt) 2021-05-31
CA2963639C (en) 2023-07-04
US9737541B2 (en) 2017-08-22
PL3204386T3 (pl) 2021-09-20
HUE054694T2 (hu) 2021-09-28
HRP20210656T1 (hr) 2021-07-23
MX388321B (es) 2025-03-19
TW201629063A (zh) 2016-08-16
JP7196270B2 (ja) 2022-12-26
EP3204386A1 (en) 2017-08-16
US20210128565A1 (en) 2021-05-06
JP2023027269A (ja) 2023-03-01
US10646493B2 (en) 2020-05-12
EP3822274B1 (en) 2024-03-06
US10149849B2 (en) 2018-12-11
EP3204386B1 (en) 2021-03-03
US20190091230A1 (en) 2019-03-28
CN113248506A (zh) 2021-08-13
AU2015328414B2 (en) 2020-03-19
DK3204386T3 (da) 2021-05-25
RS61884B1 (sr) 2021-06-30
US20200237768A1 (en) 2020-07-30
US20190336507A1 (en) 2019-11-07
US10398700B2 (en) 2019-09-03
MX2017004600A (es) 2017-06-30
AU2015328414A1 (en) 2017-04-27
AU2020201486B2 (en) 2021-07-08
JP2017530199A (ja) 2017-10-12
IL251566A0 (en) 2017-05-29
CL2017000820A1 (es) 2017-12-15
CA2963639A1 (en) 2016-04-14
IL277069B (en) 2022-05-01
SI3204386T1 (sl) 2021-08-31
ES2871142T3 (es) 2021-10-28
WO2016057370A1 (en) 2016-04-14
BR112017006998A2 (pt) 2018-01-16
SMT202100302T1 (it) 2021-07-12
EA201790779A1 (ru) 2017-09-29
JP2020033352A (ja) 2020-03-05
CY1124173T1 (el) 2022-05-27
SG10202009598VA (en) 2020-10-29
LT3204386T (lt) 2021-07-12
NZ730753A (en) 2024-02-23
IL277069A (en) 2020-10-29
IL251566B (en) 2020-09-30
JP6884701B2 (ja) 2021-06-09
EP3822274A1 (en) 2021-05-19
NZ767954A (en) 2024-02-23
ECSP17026210A (es) 2017-05-31
CN107001372A (zh) 2017-08-01
US10940152B2 (en) 2021-03-09
CN107001372B (zh) 2021-04-27
US20170296546A1 (en) 2017-10-19
ES2980464T3 (es) 2024-10-01
AU2020201486A1 (en) 2020-03-19
JP6987823B2 (ja) 2022-01-05
US20230158035A1 (en) 2023-05-25
JP2022033858A (ja) 2022-03-02
US20170042902A1 (en) 2017-02-16
KR20170063740A (ko) 2017-06-08
EP3204386A4 (en) 2018-04-18
US20160096841A1 (en) 2016-04-07
MX2021014531A (es) 2022-01-06
US11590139B2 (en) 2023-02-28
AR128748A2 (es) 2024-06-12
SG11201702759XA (en) 2017-05-30
US9512124B2 (en) 2016-12-06
CO2017003838A2 (es) 2017-07-11
KR20230035424A (ko) 2023-03-13

Similar Documents

Publication Publication Date Title
KR102504849B1 (ko) 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
EP3082819B1 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
EP3952870B1 (en) Phosphatidylinositol 3-kinase inhibitors
EP3464312A1 (en) Animal and human anti-trypanosomonal and anti-leishmania agents
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase
AU2015201030B2 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4